Key result
4-aminopyridine (4-AP) potentiated Kv2.1/Kv6.4 currents by 16% by suppressing closed-state inactivation, unlike its inhibitory effect on other Kv2.1/KvS heterotetramers.
The Kv6.4 subunit confers unique pharmacological properties to Kv2.1/Kv6.4 heterotetramers, causing 4-AP to potentiate rather than inhibit the current by modulating closed-state inactivation.
No takes yet. Share an insight, caveat, or question.
Kv2/KvS channels remain promising targets; leaves open their cardiac-specific pharmacological profiles.
Stas et al. (2015) studied this question. 4-aminopyridine (4-AP) vs. Control (no 4-AP) was evaluated on Kv2.1/Kv6.4 current amplitude. 4-aminopyridine (4-AP) potentiated Kv2.1/Kv6.4 currents by 16% by suppressing closed-state inactivation, unlike its inhibitory effect on other Kv2.1/KvS heterotetramers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: